Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.

Jeffrey How(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Travis T. Sims(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Joseph Celestino(The University of Texas MD Anderson Cancer Center), Weiyi Peng(University of Houston), Kathryn Lito(The University of Texas MD Anderson Cancer Center), Kelly M. Rangel(Cincinnati Children's Hospital Medical Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Oncology
June 1, 2023
10.1200/jco.2023.41.16_suppl.tps5619
Cited by 2

Related Papers

Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
|Cell|2017|2.6k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
|Cell Reports|2018|1.3k
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876